Neighbouring labs at the University of Cambridge are combining their expertise to understand more about how the bacteria Pseudomonas aeruginosa causes repeat infections in the lungs of people with CF.
Alyftrek, or vanza triple, is a new triple combination modulator therapy. It is made up of tezacaftor, one of the modulators used in Kaftrio, as well as two new modulators called vanzacaftor and deutivacaftor.
Please note the English survey is now closed for recruitment. However, the study is now recruiting people to complete a new survey in the following languages: French, Spanish, Italian, Polish, Romanian, Dutch and German. If you speak any of these languages, you can take part in the survey here . In Cystic Fibrosis (CF) research, we test lots of treatments to see which ones work best. To do this, we look at outcomes, which tell the researcher important information about a person's health. There are lots of ways to measure a person's health, including testing: How well their lungs work...
Trials Tracker ID
TT014747
Age range
16 years and older
Length of participation
This is a single survey that is expected to take 10-20 minutes to complete
